Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FULC
#2892
Fulcrum Therapeutics, Inc. Common Stock
7.9
1
USD
+2.33%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+2.33%
Monthly Change
+1.80%
6 month change
-9.60%
Year Change
+171.82%
Previous Close
7.7
3
Open
7.9
0
Bid
Ask
Low
7.9
0
High
7.9
1
Volume
243
Markets
US Stock Market
Healthcare
FULC
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
32.67 M
40.64 M
61.76 M
61.94 M
53.98 M
66.6 M
—
Valuation ratios
Enterprise value
325.54 M
683.46 M
452.8 M
420.99 M
195.49 M
555.72 M
1.45 B
Price to earnings ratio
—
—
-3.24
-4.53
-29.38
-9.58
-14.02
Price to sales ratio
—
—
0.06
0.16
0
—
—
Price to cash flow ratio
—
—
-0
-0
-0.13
-0.01
-0.08
Price to book ratio
—
—
0
0
0
0
0.01
Enterprise value to EBITDA ratio
-4.7
-8.78
-4.12
-3.68
-7.92
-6.44
-23.07
Profitability ratios
Return on assets %
-0.55
-0.34
-0.48
-0.38
-0.04
-0.2
-0.3
Return on equity %
-0.74
-0.38
-0.55
-0.41
-0.04
-0.21
-0.31
Return on invested capital %
-694.39
-255.15
-242.06
-217.3
-41.52
-188.47
—
Gross margin %
100
100
100
100
100
—
—
Operating margin %
-811.64
-422.97
-1 774.85
-3 945.24
-27.37
—
—
EBITDA margin %
-785.45
-406.34
-1 734.39
-4 081.39
-30.87
—
—
Net margin %
-802.66
-421.89
-1 732.43
-3 470.05
-12.16
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
4.47
11.77
12.41
17.71
22.63
27.4
98.22
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.11
0.03
0.01
0.31
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2 157.1
-1 483.69
-35.78
-948.07
-270.23
EBIT per share
—
—
-2 501.86
-1 804.99
-353.27
-1 338
-365.49
EBITDA per share
—
—
-2 444.82
-1 867.28
-398.43
-1 362.67
-364.83
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
780.11
416.95
939.15
3 117.88
3 133.39
Net current asset value per share
—
—
4 612.46
3 950.4
4 032.06
5 642.49
5 719.88
Tangible book value per share
—
—
4 421.82
3 836.13
3 920.92
5 508.64
5 518.9
Working capital per share
—
—
4 240.71
3 727.35
3 853.88
5 436.54
5 510.55
Book value per share
—
—
4 421.82
3 836.13
3 920.92
5 508.64
5 584.08
News
Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell
Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC)
Fulcrum Therapeutics stock falls as sickle cell trial misses target
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data
BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7
Stifel reiterates Fulcrum Therapeutics stock rating on drug data
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says
Fulcrum Therapeutics stock tumbles despite trial results
Fulcrum reports positive trial results for sickle cell treatment
What's Going On With Fulcrum Therapeutics Stock Tuesday? - Fulcrum Therapeutics (NASDAQ:FULC)